Skip to Main Content

Paper Details

Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Neuro Oncol
48
2016
-expressing macrophages, GSC17, GSC17 xenograft model, GSC267, Glioblastoma, HGF, MET, TEMs, TIE2, Tumor, VEGF, VEGFR2, altiratinib, bevacizumab, glioblastoma, glioblastoma stem, glioblastoma stem cell lines, hepatocyte growth factor, human, human glioblastoma stem cell, human glioblastoma stem cell lines, monocyte, mouse, myeloid cell, patients, proto-oncogene MET, stem, tumor
Author NameAffiliation
Verlene HenryThe University of Texas MD Anderson Cancer Center, Texas (V.H.) Deciphera Pharmaceuticals
John F de GrootThe University of Texas MD Anderson Cancer Center, Texas (V.H.) Deciphera Pharmaceuticals
  • 1 - 2

Datasets

Release 1.2